Literature DB >> 19497642

[Therapeutic drug option for dyslipaemia].

Antonio Maiques Galan1, Carlos Brotons Cuixart.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19497642      PMCID： PMC7022058          DOI： 10.1016/j.aprim.2009.04.008

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  31 in total

1.  Clofibrate and niacin in coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

Review 2.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.

Authors:  M R Law; N J Wald; A R Rudnicka
Journal:  BMJ       Date:  2003-06-28

3.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

4.  Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.

Authors:  Theodore Feldman; Michael Davidson; Arvind Shah; Darbie Maccubbin; Alan Meehan; Michelle Zakson; Diane Tribble; Enrico Veltri; Yale Mitchel
Journal:  Clin Ther       Date:  2006-06       Impact factor: 3.393

5.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

6.  The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.

Authors:  Kiranbir Josan; Sumit R Majumdar; Finlay A McAlister
Journal:  CMAJ       Date:  2008-02-26       Impact factor: 8.262

7.  Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Authors:  Richard H Karas; Moti L Kashyap; Robert H Knopp; Laurence H Keller; Daiva R Bajorunas; Michael H Davidson
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

8.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

Authors:  Rajesh Krishna; Matt S Anderson; Arthur J Bergman; Bo Jin; Marissa Fallon; Josee Cote; Kim Rosko; Cynthia Chavez-Eng; Ryan Lutz; Daniel M Bloomfield; Maria Gutierrez; James Doherty; Fredrick Bieberdorf; Jeffrey Chodakewitz; Keith M Gottesdiener; John A Wagner
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

9.  Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Authors:  Vasilios G Athyros; Athanasios A Papageorgiou; Valasia V Athyrou; Dimokritos S Demitriadis; Athanasios G Kontopoulos
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

Review 10.  Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.

Authors:  Tamar S Polonsky; Michael H Davidson
Journal:  Am J Cardiol       Date:  2008-04-17       Impact factor: 2.778
View more
  1 in total

1.  [Other pharmacological dyslipidemia treatment options for raising HDL-cholesterol].

Authors:  Manuel Frías Vargas; Juan Roberto Peraira Moral; Beatriz López Serrano
Journal:  Aten Primaria       Date:  2010-06-08       Impact factor: 1.137
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.